Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10734660 | 1.00 | LMNA (0.38) | LMNAALDH1A1TSHRFGFR4ALOX15 | |
| SCHEMBL24088704 | 0.95 | LMNA (0.35) | LMNA | |
| SCHEMBL19578524 | 0.83 | — | — | |
| SCHEMBL2492911 | 0.83 | — | — | |
| SCHEMBL313661 | 0.83 | — | — | |
| SCHEMBL28531104 | 0.81 | ALDH1A1 (0.33) | LMNAALDH1A1 | |
| SCHEMBL27468544 | 0.81 | LMNA (0.40) | LMNAALDH1A1TSHRFGFR4ALOX15 | |
| SCHEMBL4187921 | 0.80 | LMNA (0.35) | LMNAALDH1A1TSHRFGFR4 | |
| SCHEMBL10082810 | 0.80 | GRIK1 (0.37) | LMNAALDH1A1 | |
| SCHEMBL24022689 | 0.80 | LMNA (0.41) | LMNAALDH1A1TSHRALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021099937-A1 | HYDROPHILIC POLYIMIDE, MEMBRANES PREPARED THEREFROM, AND USES THEREOF | KYOTO UNIVERSITY (JP) | 2021-05-27 | — | — | WO | disclosed |
| US-20200301275-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-11 | — | — | US | disclosed |
| US-9758642-B2 | Rubber mixtures containing silicic acid and sulfur-containing additives | LANXESS DEUTSCHLAND GMBH (DE) | 2017-09-12 | — | — | US | disclosed |
| US-20170175078-A1 | CELL CULTURE SUBSTRATE COMPRISING FLUORINE-CONTAINING POLYMER ON ITS SURFACE | NIPPON SHOKUBAI, CO., LTD. (JP) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314820-B2 | Imidazole-based heterocyclic compounds | MIF, SLC11A2, TLR5 | LMNA 4294/4885ALDH1A1 370/4885TSHR 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.